No Data
Frontier Biotech 2025 Annual Performance Quick Report and Correction Announcement of the Performance Forecast
Summary of Frontier Biotech\'s 2025 Annual Report
Frontier Biotech\'s First Quarter Report for 2026
Frontier Biotechnologies 2025 Annual Report
China Approves Frontier Biotechnologies' Trial for Chronic Kidney Disease Injection
STAR Market Daily: Frontier Biotechnologies Receives $40 Million Upfront Payment from GlaxoSmithKline; Fengmao Technology to Raise Prices on All Products Starting April 1
①Shareholders of Hengshuo Corporation plan to collectively reduce their holdings by no more than 3% of the company’s shares; ②Puyu Investment plans to increase its stake in Tiandeju by purchasing shares worth between 20 million and 40 million yuan; ③Xgimi Technology's wholly-owned subsidiary has been awarded a development contract for automotive projection systems by an automobile manufacturer; ④Mao Liping, a shareholder of Aibomed, plans to reduce his stake by no more than 1% of the company’s shares.